Troubled KV Pharma hands CEO big raise; CMC buys biologics manufacturing facility; Astellas inks discovery pact on chagas disease;

Conversations on Twitter :

 @FierceBiotech: CIRM favors teamwork with $150M in new stem cell grants. Story | Follow @FierceBiotech

 @JohnCFierce: Deja vu: Dimebon (remember it?) promising in mouse study for Alzheimer's. Scientists want to go back, try again. Release | Follow @JohnCFierce

 @RyanMFierce: Biotech VC deals abound this week: Ultragenyx nailed down $15M, and now Mersana says it's found $27M more with help from deep pockets at NEA. | Follow @RyanMFierce

> KV Pharma may be threatening to file bankruptcy as compounding pharmacies continues to undercut its new drug to prevent premature births, but CEO Greg Divis still warranted a big pay hike. Story

> Remember Dimebon, the experimental Alzheimer's drug that flunked a series of expensive late-stage studies and cost Pfizer a fortune? Scientists at Mt. Sinai say they've put it through mouse tests again--where it proved positive. Now they want to try again and see whether the once-promising compound could work for a certain population. Release

> Astellas Pharma inked a research pact with the Tokyo Institute of Technology in which they will search for new drugs to treat diseases caused by protozoan parasites, such as chagas disease. Story

> CMC Biologics has acquired Xoma's large-scale biologics manufacturing operations in Berkeley, CA. Release

> Australia's Novogen is merging into the U.S.-based devices company Kai Medical. It's selling its glucan tech to TR Therapeutics. Story

Pharma News

 @FiercePharma: WSJ's list of 25 Best CFOs includes 3 drug company execs: Biogen, Allergan, Perrigo. List | Follow @FiercePharma

> Pfizer nears animal health IPO as cost-cutting boosts profits. Story

> Glaxo changes the guard at newly bought HGS. News

> Dendreon to slash 600 more jobs as Provenge sales lag. Article

> FDA nixes new gout use for Regeneron's Arcalyst. Item

Medical Device News

@FierceMedDev: Italy's DiaSorin Group signed a Dx expansion deal with Trivitron for the Indian market. Asian expansion continues. Release | Follow @FierceMedDev

 @MarkHFierce: 23andMe will seek FDA 510(k) clearance for its new personalized DNA test, the company disclosed. Release | Follow @MarkHFierce

 @DamianFierce: Looking to boost its flagging CRM business, Boston Sci snagged CE marks for two MRI-friendly pacemakers. More | Follow @DamianFierce

> Medtronic nabs 510(k) for combination surgical device. Item

> Teleflex hit with Class I recall of venous catheter. Story

Biotech Research News

> Another shot at treating Alzheimer's with Dimebon? Article

> 17 universities win NIH cash for tissue chip/drug safety testing. News

> CIRM favors teamwork with $150M in new stem cell grants. More

Pharma Manufacturing News

 @EricPFierce: It is out with the old and with the new at HGS now that GSK is in charge. More | Follow @EricPFierce

> Plant's IT mess nearly kills AZ growth in new markets. News

> Drug pricing figures into McKesson settlement, earnings. Article

And Finally… Scientists used stem cells to regrow craniofacial tissues in the first human study of its kind. Release

 

Suggested Articles

Nearly two years after raising $75 million, iTeos Therapeutics is picking up $125 million to push its lead assets through phase 1/2 trials.

Bristol Myers Squibb and bluebird bio filed their BCMA-targeting CAR-T therapy for FDA approval, teeing it up for a potential green light in 2020.

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.